Further trials, dedicated to renal outcomes, confirmed this benefit of SGLT2 inhibitors: the CREDENCE trial [83], conducted in patients with type 2 diabetes and CKD showed a 27% risk reduction in the composite renal outcome (end-stage renal disease, doubling of serum creatinine, or renal or cardiovascular death). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.